Combined type 2 diabetes and obesity is a significant global health challenge. Despite our increased awareness of pathogenic mechanisms and intense drug development in the field, new strategies are urgently needed if we are to stem the tide. Endobarrier is a novel device, which part-mimics Roux-en-Y gastric bypass surgery, which we know to be effective in diabetes. The use of an implantable intestinal device to treat diabetes is an exciting concept.

In this issue of *Practical Diabetes*, Dr Longcroft-Wheaton and Professor Bhandari review the evidence base behind Endobarrier and debate its place in treatment algorithms. They conclude that its current role is unclear and there is not enough evidence for it to replace bariatric surgery as a treatment option, though it may be used as a 'bridging procedure' to enable safer operating conditions. They call for device registries and further research.

Certainly, efficacy data with Endobarrier use have been encouraging, but this needs to be balanced with study limitations that include trials with small numbers of patients, often lacking a control group and with restricted implant duration and follow up.

REVISE-Diabesity seeks to address some of these limitations. It is a randomised controlled clinical trial, taking place in an NHS setting, involving 72 patients with a one-year implant duration and a one-year post-removal follow up. It has been independently initiated and funded by the Association of British Clinical Diabetologists (ABCD), and seeks to evaluate combined use of GLP-1 receptor agonist and Endobarrier compared to Endobarrier alone as well as incorporating exciting mechanistic aspects.

Therefore, although it is known where the device should be anatomically placed, following this study, we should be able to better establish 'where' to place the Endobarrier in the patient treatment pathway.

For further information, please refer to the ABCD website: www.diabetologists-abcd.org.uk/research/endobarrier_study.htm.

**P Sen Gupta,** MBBS, BMedSci, MRCP,
ABCD Research Fellow,
City Hospital Birmingham
and King’s College London, UK

**Declaration of interests**
The author is currently conducting a clinical trial involving the use of Endobarrier.